MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD

Reuters

2025/10/30

MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD

Mind Medicine (MindMed) Inc. has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2579515632"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579515632\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579515632?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 08:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579515632","market":"us","top_or_hot":-1,"title":"MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 08:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/MNMD\">Mind Medicine (MindMed) Inc.</a> has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nNDL1TlVHF:1","article_id":"2579515632","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579515632","pubTimestamp":1761782485,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mind Medicine  Inc. has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder  and major depressive disorder . The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide acc","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","BK4547":"WSB热门概念"},"translate_title":"MindMed推出新的公司演示文稿，强调后期管道以及对GAD和MDD的战略重点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNMD":0.9},"content_text":"MindMed Unveils New Corporate Presentation Highlighting Late-Stage Pipeline and Strategic Focus on GAD and MDD\n    \n\nMind Medicine (MindMed) Inc. has released a corporate presentation highlighting its strategic focus on developing treatments for generalized anxiety disorder (GAD) and major depressive disorder (MDD). The company is advancing its lead clinical program, MM120 ODT, which is currently in ongoing Phase 3 studies for both indications. MindMed reports a strong financial position, with $209.1 million in cash, cash equivalents, and investments as of September 30, 2025, and anticipates a cash runway extending into 2027. The company expects three Phase 3 readouts in 2026, targeting potential commercial opportunities in the GAD and MDD markets. Key milestones include topline readouts from MM120-300 and MM120-301 for GAD and MM120-310 for MDD in 2026, with an additional Phase 3 study for MDD scheduled to begin mid-2026. You can access the full presentation through the link below.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mind Medicine (MindMed) Inc. published the original content used to generate this news brief on October 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}